Soluble guanylate cyclase: a potential therapeutic target for heart failure-Reference-Cited by-同舟云学术

Soluble guanylate cyclase: a potential therapeutic target for heart failure

Published:2012-05-24 Issue:2 Volume:18 Page:123-134
ISSN:1382-4147
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Gheorghiade Mihai,Marti Catherine N.,Sabbah Hani N.,Roessig Lothar,Greene Stephen J.,Böhm Michael,Burnett John C.,Campia Umberto,Cleland John G. F.,Collins Sean P.,Fonarow Gregg C.,Levy Phillip D.,Metra Marco,Pitt Bertram,Ponikowski Piotr,Sato Naoki,Voors Adriaan A.,Stasch Johannes-Peter,Butler Javed

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10741-012-9323-1.pdf

Reference93 articles.

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J (2010) Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121(7):e46–e215. doi: 10.1161/CIRCULATIONAHA.109.192667

2. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O’Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296(18):2217–2226. doi: 10.1001/jama.296.18.2217

3. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319–1331. doi: 10.1001/jama.297.12.1319

4. Wilcox JE, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Heywood JT, Inge PJ, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN, Gheorghiade M (2012) Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J 163(1):49–56.e2. doi: 10.1016/j.ahj.2011.10.001

5. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O’Connell J, O’Connor CM, Pang PS, Pina IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N (2009) Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 157(6):957–970. doi: 10.1016/j.ahj.2009.04.010

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Mechanism of Soluble Guanylate Cyclase-Veliciguat for Heart Failure;Advances in Clinical Medicine;2024

2. Mitochondrial and Proteasome Dysfunction Occurs in the Hearts of Mice Treated with Triazine Herbicide Prometryn;International Journal of Molecular Sciences;2023-10-17

3. Pulmonary Hypertension Associated with Left Heart Disease;Seminars in Respiratory and Critical Care Medicine;2023-09-14

4. Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction;Journal of Cardiovascular Development and Disease;2023-09-08

5. Uso de vericiguat en pacientes con falla cardiaca y fracción de eyección reducida;Revista Ciencia Multidisciplinaria CUNORI;2023-09-08